STAQ Pharma Launches Oncology Portfolio to Address Critical Drug Shortages
Improving the Supply of Critical Medications for Pediatric and Adult Cancer Patients
Columbus, OH – August 1, 2024 – STAQ Pharma, a hospital-owned 503B outsourcing supplier committed to alleviating drug shortages, announced the launch of their oncology portfolio at a ceremony held at their Columbus, OH, facility on Friday, July 26. The oncology portfolio begins with methotrexate, an essential treatment widely used for pediatric cancer patients. STAQ Pharma hopes to provide relief for hospital and healthcare system supply chains as an onshore supplier with the release of its first commercial batch of oncology medications.
The successful production of methotrexate comes from their newest manufacturing facility in Columbus, OH, which was specifically designed to produce hazardous drugs such as oncology medications. In addition to the production of essential oncology drugs, the Columbus facility addresses drug shortages in the sterile injectable market.
“Successfully producing methotrexate is a major milestone in addressing the critical needs of pediatric cancer patients,” stated Terri Wilson, Vice President of Pharmacy for the Children’s Hospital Association. “Production capabilities like those at STAQ Pharma are crucial for supporting a consistent supply of essential oncology drugs. This commitment is vital for vulnerable cancer patients, and STAQ’s efforts significantly mitigate drug shortages that can jeopardize treatment outcomes.”
With plans to expand the oncology portfolio, STAQ Pharma is having ongoing conversations with hospital partners to determine the next essential oncology medication on the FDA Shortage List for production.
“The fact that we’ve been able to produce methotrexate out of our new Columbus facility speaks volumes to our commitment to accessible healthcare by combating drug shortages,” states Joe Bagan, CEO of STAQ Pharma. “Through the focus on the production of hazardous drugs, we hope to assure a stable supply of oncology medications within the country. Our company will closely work with hospitals and healthcare providers to make sure that the treatment needs of vulnerable patients, especially children fighting against cancer, are met.”
The event was highlighted by the presence of healthcare leaders, community members, and staff from Ohio’s Congressional offices, including both U.S. Senators. U.S. Congressman Mike Carey, representing STAQ Pharma’s district, also addressed the audience.
STAQ Pharma enters the oncologic drugs market at a point when essential medication shortages challenge health providers across the nation. Through safe production and rigorous quality assurance, STAQ Pharma remains dedicated to the reliable supply of essential oncology medications to ensure treatment for pediatric and adult cancer patients.
About STAQ Pharma
As a trusted and reliable supplier to hospitals and healthcare systems nationwide, STAQ Pharma is dedicated to addressing critical drug shortages and ensuring vital medications for all patients. Our commitment to Safety, Transparency, Availability, and Quality is reflected in our two state-of-the-art 503B outsourcing facilities built to cGMP standards. STAQ Pharma’s unique ownership model with hospitals allows us to precisely meet healthcare provider needs. With unwavering dedication, STAQ Pharma tackles the drug shortage crisis, delivering vital, safe, and effective medications to hospitals, ambulatory surgery centers, and healthcare facilities across the nation.
FORWARD LOOKING STATEMENT
Forward-Looking Statements in this press release, which are not historical facts, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Our actual results, performance or achievements may differ materially from those expressed or implied by these forward-looking statements. Such forward-looking statements are necessarily based upon estimates and assumptions that, while considered reasonable by us and our management, are inherently uncertain. We caution you not to place undue reliance on any forward-looking statements, which are made as of the date of this press release. We undertake no obligation to update publicly any of these forward-looking statements to reflect actual results, new information or future events, changes in assumptions or changes in other factors affecting forward-looking statements, except to the extent required by applicable laws. If we update one or more forward-looking statements, no inference should be drawn that we will make additional updates with respect to those or other forward-looking statements.